Recs

0

Merck Enters Share Repurchase Agreement With Goldman Sachs

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

As part of an overall stock buyback scheme, Merck (NYSE: MRK  ) has launched an accelerated repurchase program to buy shares held by Goldman Sachs (NYSE: GS  ) . All told, the pharmaceutical company will purchase $5 billion worth of its stock from the investment bank.

That figure equates to roughly 99.5 million shares. The transaction is expected to be completed by Nov. 25 of this year.

Merck has been quite busy in the stock buyback sphere of late. As of April 30, the firm's total outstanding authorization for such activity stood at $16.1 billion. In the first four months of this year, it bought back around 17.8 million shares, spending $772 million to do so.


Read/Post Comments (0) | Recommend This Article (0)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2445634, ~/Articles/ArticleHandler.aspx, 8/23/2016 9:43:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 27 minutes ago Sponsored by:
DOW 18,547.30 17.88 0.10%
S&P 500 2,186.90 4.26 0.20%
NASD 5,260.08 15.48 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/23/2016 4:00 PM
MRK $63.58 Up +0.03 +0.05%
Merck and Co. CAPS Rating: ****

Advertisement